ProQR Therapeutics (PRQR) Short term Debt (2013 - 2026)

ProQR Therapeutics has reported Short term Debt for 14 years, with the latest figure at $5.8 million in Q1 2026.

• Quarterly Short term Debt rose 18.23% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 18.23% YoY) and the FY2025 annual result came in at $5.7 million, up 15.83% from the prior year.
• Short term Debt advanced to $5.8 million in Q1 2026 per PRQR's latest filing, from $5.7 million in the prior quarter.
• Over five years, Short term Debt peaked at $43.1 million in Q1 2022 and troughed at $2.6 million in Q4 2022.
• A 5-year average of $9.3 million and a median of $4.9 million in 2025 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2022 and 2023: Short term Debt soared 216181.09% in 2022, then plunged 90.34% in 2023.
• Over 5 years, Short term Debt stood at $2.6 million in 2022, then gained by 23.39% to $3.1 million in 2023, then soared by 55.58% to $4.9 million in 2024, then advanced by 15.83% to $5.7 million in 2025, then advanced by 2.08% to $5.8 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $5.8 million, $5.7 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.